Scientists probe why glioblastoma strikes men harder

NCT ID NCT07472387

Not yet recruiting Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how male hormones (androgens) influence the immune cells around glioblastoma tumors, the most common and aggressive brain cancer in adults. Researchers will collect blood, saliva, and stool samples from 40 newly diagnosed patients before and after standard chemoradiotherapy. The goal is to understand why men are more likely to get this cancer and have worse outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could reveal why glioblastoma is more common and aggressive in men, potentially pointing toward sex-specific treatment approaches.
What could go wrong: This is an observational study with no treatment being tested, so it will not directly benefit participants. The findings may not lead to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA (GBM)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Neuro-oncology department, Pitié Salpêtrière hospital

Paris, 75013, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.